Cingulate Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CING, updated each market day.
CING AI Sentiment
AI predicts Cingulate Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Cingulate Inc. Common Stock
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Sector
Exchange
Market Cap
$69,306,533
Cap Tier
Employees
14
Headquarters
KANSAS CITY, KS
Listed Since
Dec. 8, 2021
Website
CING Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CING Volatility
Cingulate Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
